The stock of Bluebird bio Inc (BLUE) has seen a -1.29% decrease in the past week, with a 5.66% gain in the past month, and a -59.94% decrease in the past quarter. The volatility ratio for the week is 3.72%, and the volatility levels for the past 30 days are at 7.74% for BLUE. The simple moving average for the last 20 days is -0.53% for BLUE’s stock, with a simple moving average of -49.73% for the last 200 days.
Is It Worth Investing in Bluebird bio Inc (NASDAQ: BLUE) Right Now?
Moreover, the 36-month beta value for BLUE is 0.77. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 5 as “overweight,” 5 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BLUE is 192.36M and currently, short sellers hold a 25.47% of that float. On October 22, 2024, BLUE’s average trading volume was 7.35M shares.
BLUE) stock’s latest price update
The stock of Bluebird bio Inc (NASDAQ: BLUE) has increased by 1.22 when compared to last closing price of 0.49.Despite this, the company has seen a loss of -1.29% in its stock price over the last five trading days. gurufocus.com reported 2024-10-08 that Bluebird Bio (BLUE, Financial) experienced a significant drop in its stock price, declining by 5.67%. The shares are currently trading at $0.491, with a trading volume of 3.72 million shares, a turnover rate of 1.92%, and showing a price amplitude of 4.76%.
Analysts’ Opinion of BLUE
Morgan Stanley gave a rating of “Equal-Weight” to BLUE, setting the target price at $7 in the report published on December 08th of the previous year.
BLUE Trading at -14.13% from the 50-Day Moving Average
After a stumble in the market that brought BLUE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.02% of loss for the given period.
Volatility was left at 7.74%, however, over the last 30 days, the volatility rate increased by 3.72%, as shares surge +1.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -50.12% lower at present.
During the last 5 trading sessions, BLUE fell by -1.29%, which changed the moving average for the period of 200-days by -65.74% in comparison to the 20-day moving average, which settled at $0.4994. In addition, Bluebird bio Inc saw -64.00% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BLUE starting from Klima Thomas J, who sale 1,006 shares at the price of $0.53 back on Sep 30 ’24. After this action, Klima Thomas J now owns 170,000 shares of Bluebird bio Inc, valued at $529 using the latest closing price.
Obenshain Andrew, the President and CEO of Bluebird bio Inc, sale 34,780 shares at $0.53 during a trade that took place back on Sep 30 ’24, which means that Obenshain Andrew is holding 375,218 shares at $18,270 based on the most recent closing price.
Stock Fundamentals for BLUE
Current profitability levels for the company are sitting at:
- -6.09 for the present operating margin
- -0.37 for the gross margin
The net margin for Bluebird bio Inc stands at -5.67. The total capital return value is set at -1.35. Equity return is now at value -177.63, with -50.27 for asset returns.
Based on Bluebird bio Inc (BLUE), the company’s capital structure generated 0.88 points at debt to capital in total, while cash flow to debt ratio is standing at -0.55. The debt to equity ratio resting at 7.37. The interest coverage ratio of the stock is -32.45.
Currently, EBITDA for the company is -167.16 million with net debt to EBITDA at -1.22. When we switch over and look at the enterprise to sales, we see a ratio of 6.24. The receivables turnover for the company is 3.52for trailing twelve months and the total asset turnover is 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.68.
Conclusion
To wrap up, the performance of Bluebird bio Inc (BLUE) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
